# Optimizing Induction Chemotherapy Regimens for ND Elderly AML Patients Who Are Eligible for Intense Chemotherapy

> **NCT06066242** · NA · ACTIVE_NOT_RECRUITING · sponsor: **Institute of Hematology & Blood Diseases Hospital, China** · enrollment: 113 (actual)

## Conditions studied

- Acute Myeloid Leukemia

## Interventions

- **OTHER:** Different induction chemotherapy regimens

## Key facts

- **NCT ID:** NCT06066242
- **Lead sponsor:** Institute of Hematology & Blood Diseases Hospital, China
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-10-01
- **Primary completion:** 2027-10-20
- **Final completion:** 2028-05-10
- **Target enrollment:** 113 (ACTUAL)
- **Last updated:** 2026-05-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06066242

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06066242, "Optimizing Induction Chemotherapy Regimens for ND Elderly AML Patients Who Are Eligible for Intense Chemotherapy". Retrieved via MORVS 2026-10-18 from https://api.morvs.ai/clinical/NCT06066242. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*